INSPIRED BY PATIENTS DRIVEN BY RNA

INSPIRED BY PATIENTS DRIVEN BY RNAINSPIRED BY PATIENTS DRIVEN BY RNAINSPIRED BY PATIENTS DRIVEN BY RNA

Developing RNAi therapies for Cardiovascular and Cardiometabolic disease

INSPIRED BY PATIENTS DRIVEN BY RNA

INSPIRED BY PATIENTS DRIVEN BY RNAINSPIRED BY PATIENTS DRIVEN BY RNAINSPIRED BY PATIENTS DRIVEN BY RNA

Developing RNAi therapies for Cardiovascular and Cardiometabolic disease

Transformative therapies

We are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of RNAi therapies to treat illnesses where no other treatments have proven effective or ever existed.

Therapy pipeline

We have a rich therapy pipeline in Hypertrophic cardiomyopathy, Heart failure and Cardiotoxicity. Strategies employed in these therapies include cellular metabolic modulation and the reactivation of cardiac regeneration. 

Technology behind the pipeline

We are at the forefront of translating Ai-driven big data analysis into precision preclinical disease models for therapeutic RNAi validation. This synergistic workflow expedites RNAi target discovery and efficacy validation.

Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

image152

Genome Biologics is recipient of the European Union H2020 SME Instrument Phase 1 and 2 award